Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK105 (Penpulimab) in Metastatic Nasopharyngeal Carcinoma
NCT03866967Phase 2Completed
- Sponsor
- Akeso, Inc.
- Start
- Mar 2019
- Primary completion
- Mar 2021
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of penpulimab in nasopharyngeal carcinoma (NPC), sponsored by Akeso, Inc.. Started Mar 2019; status: completed.
02
Drugs
penpulimab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03866967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866967.